Literature DB >> 8446511

A rationale for dietary intervention in postmenopausal breast cancer patients: an update.

L A Cohen1, D P Rose, E L Wynder.   

Abstract

In 1982, we proposed a large-scale randomized prospective trial to test the hypothesis that decreasing dietary fat intake from 38% to 20% of total calories would increase the disease-free interval and/or five-year survival rate for postmenopausal breast cancer patients. We now review new evidence from epidemiological studies, laboratory animal model studies, and preliminary feasibility trials that has accumulated over the past decade, in support of such a trial, and suggest that a more appropriate dietary goal is a reduction in fat intake to 15% of total calories.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8446511     DOI: 10.1080/01635589309514231

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  4 in total

1.  Adenine-DNA adduct derived from the nitroreduction of 6-nitrochrysene is more resistant to nucleotide excision repair than guanine-DNA adducts.

Authors:  Jacek Krzeminski; Konstantin Kropachev; Dara Reeves; Aleksandr Kolbanovskiy; Marina Kolbanovskiy; Kun-Ming Chen; Arun K Sharma; Nicholas Geacintov; Shantu Amin; Karam El-Bayoumy
Journal:  Chem Res Toxicol       Date:  2013-10-30       Impact factor: 3.739

2.  Safety of tamoxifen.

Authors:  G M Williams
Journal:  BMJ       Date:  1994-02-19

3.  Inefficient nucleotide excision repair in human cell extracts of the N-(deoxyguanosin-8-yl)-6-aminochrysene and 5-(deoxyguanosin-N(2)-yl)-6-aminochrysene adducts derived from 6-nitrochrysene.

Authors:  Jacek Krzeminski; Konstantin Kropachev; Marina Kolbanovskiy; Dara Reeves; Alexander Kolbanovskiy; Byeong-Hwa Yun; Nicholas E Geacintov; Shantu Amin; Karam El-Bayoumy
Journal:  Chem Res Toxicol       Date:  2010-11-29       Impact factor: 3.739

4.  An examination of obesity and breast cancer survival in post-menopausal women.

Authors:  A Katoh; V J Watzlaf; F D'Amico
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.